Cover Image
市場調查報告書

伊波拉病毒感染疾病:開發平台分析

Ebola Viral Infections - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 264102
出版日期 內容資訊 英文 282 Pages
訂單完成後即時交付
價格
Back to Top
伊波拉病毒感染疾病:開發平台分析 Ebola Viral Infections - Pipeline Review, H1 2016
出版日期: 2016年05月25日 內容資訊: 英文 282 Pages
簡介

伊波拉病毒感染是會造成人體內外出血,可稱之為絕症的疾病。主要的症狀有發燒及嚴重頭痛、關節痛、肌肉痛、喉嚨痛、噁心嘔吐、下痢、胸痛、咳嗽等。主要治療法有氧氣療法和輸血,經靜脈(IV)輸液,止痛藥等。

本報告提供全球各國治療伊波拉病毒感染疾病所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

伊波拉病毒感染疾病概要

治療藥的開發

  • 伊波拉病毒感染疾病開發中產品:概要
  • 伊波拉病毒感染疾病開發中產品:比較分析

各企業開發中的伊波拉病毒感染疾病治療藥

大學/研究機關研究中的伊波拉病毒感染疾病治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

伊波拉病毒感染疾病治療藥:開發中的產品一覽(各企業)

伊波拉病毒感染疾病治療藥:研究中的產品一覽(各大學/研究機關)

伊波拉病毒感染疾病治療藥的開發企業

  • Abivax S.A.
  • AnGes MG, Inc.
  • ANP Technologies, Inc.
  • Arno Therapeutics, Inc.
  • Avipero Limited
  • BioCryst Pharmaceuticals, Inc.
  • BioFactura, Inc.
  • Celgene Corporation
  • Emergent BioSolutions Inc.
  • Enyo Pharma S.A.S.
  • Etubics Corporation
  • GeoVax Labs, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Globavir Biosciences, Inc.
  • Hemispherx Biopharma, Inc.
  • Humabs BioMed SA
  • Immune Response BioPharma, Inc.
  • Immunovaccine, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Integrated BioTherapeutics, Inc.
  • Johnson & Johnson
  • Kineta, Inc
  • Kymab Limited
  • Merck & Co., Inc.
  • Microbiotix, Inc.
  • Micropharm Limited
  • NanoViricides, Inc.
  • Navigen Pharmaceuticals, Inc.
  • Novavax, Inc.
  • Peregrine Pharmaceuticals, Inc.
  • Phelix Therapeutics, LLC
  • Profectus BioSciences, Inc.
  • RedHill Biopharma Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • SignPath Pharma Inc
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Sirnaomics, Inc.
  • Soligenix, Inc.
  • Taiga Biotechnologies, Inc.
  • Tamir Biotechnology, Inc.
  • TGV-Laboratories
  • 富山化學工業
  • Vaxeal Holding SA
  • XBiotech USA, Inc.

伊波拉病毒感染疾病:治療藥的評估

  • 單劑治療藥的情況
  • 並用
  • 並用治療藥的情況
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

伊波拉病毒感染疾病治療藥:開發中產品的最新趨勢

伊波拉病毒感染疾病治療藥:暫停開發的產品

伊波拉病毒感染疾病治療藥:中止開發的產品

伊波拉病毒感染疾病相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8001IDB

Summary

Global Markets Direct's, 'Ebola Viral Infections - Pipeline Review, H1 2016', provides an overview of the Ebola Viral Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ebola Viral Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ebola Viral Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections
  • The report reviews pipeline therapeutics for Ebola Viral Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ebola Viral Infections therapeutics and enlists all their major and minor projects
  • The report assesses Ebola Viral Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ebola Viral Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ebola Viral Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Ebola Viral Infections Overview
  • Therapeutics Development
  • Ebola Viral Infections - Therapeutics under Development by Companies
  • Ebola Viral Infections - Therapeutics under Investigation by Universities/Institutes
  • Ebola Viral Infections - Pipeline Products Glance
  • Ebola Viral Infections - Products under Development by Companies
  • Ebola Viral Infections - Products under Investigation by Universities/Institutes
  • Ebola Viral Infections - Companies Involved in Therapeutics Development
  • Ebola Viral Infections - Therapeutics Assessment
  • Drug Profiles
  • Ebola Viral Infections - Recent Pipeline Updates
  • Ebola Viral Infections - Dormant Projects
  • Ebola Viral Infections - Discontinued Products
  • Ebola Viral Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ebola Viral Infections, H1 2016
  • Number of Products under Development for Ebola Viral Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Ebola Viral Infections - Pipeline by Abivax S.A., H1 2016
  • Ebola Viral Infections - Pipeline by AnGes MG, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by ANP Technologies, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Avipero Limited, H1 2016
  • Ebola Viral Infections - Pipeline by BioCryst Pharmaceuticals, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by BioFactura, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Celgene Corporation, H1 2016
  • Ebola Viral Infections - Pipeline by Emergent BioSolutions Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Enyo Pharma S.A.S., H1 2016
  • Ebola Viral Infections - Pipeline by Etubics Corporation, H1 2016
  • Ebola Viral Infections - Pipeline by GeoVax Labs, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Gilead Sciences, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Ebola Viral Infections - Pipeline by Globavir Biosciences, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Hemispherx Biopharma, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Humabs BioMed SA, H1 2016
  • Ebola Viral Infections - Pipeline by Immune Response BioPharma, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Immunovaccine, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Integrated BioTherapeutics, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Johnson & Johnson, H1 2016
  • Ebola Viral Infections - Pipeline by Kineta, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Kymab Limited, H1 2016
  • Ebola Viral Infections - Pipeline by Merck & Co., Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Microbiotix, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Micropharm Limited, H1 2016
  • Ebola Viral Infections - Pipeline by NanoViricides, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Novavax, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Phelix Therapeutics, LLC, H1 2016
  • Ebola Viral Infections - Pipeline by Profectus BioSciences, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Ebola Viral Infections - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by SignPath Pharma Inc, H1 2016
  • Ebola Viral Infections - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016
  • Ebola Viral Infections - Pipeline by Sirnaomics, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Soligenix, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Taiga Biotechnologies, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Tamir Biotechnology, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by TGV-Laboratories, H1 2016
  • Ebola Viral Infections - Pipeline by Toyama Chemical Co., Ltd., H1 2016
  • Ebola Viral Infections - Pipeline by Vaxeal Holding SA, H1 2016
  • Ebola Viral Infections - Pipeline by XBiotech USA, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Ebola Viral Infections Therapeutics - Recent Pipeline Updates, H1 2016
  • Ebola Viral Infections - Dormant Projects, H1 2016
  • Ebola Viral Infections - Dormant Projects (Contd..1), H1 2016
  • Ebola Viral Infections - Dormant Projects (Contd..2), H1 2016
  • Ebola Viral Infections - Dormant Projects (Contd..3), H1 2016
  • Ebola Viral Infections - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Ebola Viral Infections, H1 2016
  • Number of Products under Development for Ebola Viral Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top